Commonly used cholesterol calculation underestimates heart disease danger for many

March 26, 2013, Johns Hopkins University School of Medicine

In what promises to be an eye-opener for many doctors and patients who routinely depend on cholesterol testing, a study led by researchers at the Johns Hopkins University School of Medicine found that the standard formula used for decades to calculate low-density lipoprotein (LDL) cholesterol levels is often inaccurate. Of most concern, the researchers say, is their finding that the widely used formula underestimates LDL where accuracy matters most—in the range considered desirable for high-risk patients. Results of the study are published in an online article, ahead of print, in the Journal of the American College of Cardiology.

LDL is known as the "bad" , with higher numbers signaling greater risk of plaque accumulating in and having a heart attack. Since 1972, a formula called the Friedewald equation has been used to gauge LDL cholesterol. It is an estimate rather than an exact measurement. However, physicians use the number to assess their patients' risk and determine the best course of treatment.

"In our study, we compared samples assessed using the Friedewald equation with a direct calculation of the LDL cholesterol. We found that in nearly one out of four samples in the 'desirable' range for people with a higher , the Friedewald equation had it wrong," says Seth Martin, M.D., a clinical fellow at the Johns Hopkins Ciccarone Center for the Prevention of . "As a result, many patients may think they achieved their LDL cholesterol target when, in fact, they may need more to reduce their heart disease risk," says Martin, who is the lead author of the study.

"In patients with heart disease, we want to get their below 70—that is the typical goal," says Steven Jones, M.D., director of inpatient cardiology at The Johns Hopkins Hospital and a faculty member at the Ciccarone Center who is the senior author of the study. Jones says based on their findings, many people—especially those with high triglyceride levels—may have a false sense of assurance that their LDL cholesterol targets have been met.

For the study, the researchers obtained detailed lipid profiles of more than 1.3 million American adults—almost one out of every 180 adults in the United States—analyzed from 2009 to 2011. The LDL cholesterol and other blood lipid components in those samples had been directly measured with a technique known as ultracentrifugation. The researchers then evaluated those samples using the Friedewald equation that is used routinely in doctors' offices worldwide. When they compared the results, the differences came to light.

The lipid profiles were from a laboratory in Birmingham, Alabama, that provides a detailed analysis of samples sent in by doctors across the country. Except for the age of people on whom the samples were based (59 years on average) and the gender (52 percent of the samples were from women), the patients were not identifiable to the researchers. The researchers collaborated with the lab to develop the database they would need for the study.

The Friedewald equation was introduced into clinical practice by William Friedewald, M.D., to work around the significant time and expense of ultracentrifugation specifically to measure LDL cholesterol among about 400 people in families with genetic cholesterol abnormalities. The equation calculates LDL cholesterol with the following formula: total cholesterol minus HDL cholesterol minus triglycerides divided by five. The result is expressed in milligrams per deciliter.

"The database that we used was almost 3,000 times larger than the sample used to devise the Friedewald equation," Martin says.

As an alternative to Friedewald, Martin and his colleagues suggest that a more accurate way to assess risk for patients is to look at non-HDL, which is acquired by subtracting HDL from total cholesterol.

That non-HDL number, which includes LDL and other plaque-causing cholesterol particles called VLDL (very ), would typically be about 30 points higher than when LDL cholesterol is calculated under the Friedewald method, and it could vary. But Martin says it would provide a better way to assess whether patients need to modify their medications or make more substantial lifestyle changes. "Most specialists in our field agree at this point that all of those non-HDL components are important," he says.

The non-HDL cholesterol level can be obtained easily using the same test widely available in doctors' offices today at no greater cost than the Friedewald calculation.

"Non-HDL cholesterol is a much better target for quantifying risk of plaques in coronary arteries," says Jones. "Looking at non-HDL cholesterol would make it simpler and more consistent, and would enable us to provide our patients with a better assessment," he says.

Jones, who originated the idea to use the large laboratory database to assess the Friedewald equation, says the information was provided by the lab at no cost. The lab, Atherotech, did not provide any funding for the research. The database used in the study is registered on the website http://www.clinicaltrials.gov and will be an important resource for ongoing scientific investigation.

Explore further: Photographic cholesterol test

Related Stories

Photographic cholesterol test

August 17, 2012
Researchers in India have developed a total cholesterol test that uses a digital camera to take a snapshot of the back of the patient's hand rather than a blood sample. The image obtained is cropped and compared with images ...

'Bad' cholesterol not as bad as people think, study shows

May 5, 2011
The so-called "bad cholesterol" – low-density lipoprotein commonly called LDL – may not be so bad after all, shows a Texas A&M University study that casts new light on the cholesterol debate, particularly among ...

Non-HDL-C level associated with risk of major cardiovascular events among patients taking statins

March 27, 2012
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels ...

Low 'bad' cholesterol levels may be linked to cancer risk

March 26, 2012
(HealthDay) -- There may be a link between low levels of "bad" low-density lipoprotein (LDL) cholesterol and increased cancer risk, according to new research.

Machine similar to dialysis removes cholesterol from blood

March 1, 2013
Some patients are genetically prone to such dangerously high levels of cholesterol that no amount of diet, exercise and medications can reduce their cholesterol to safe levels.

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.